On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.
The downgrade comes a day after Alnylam released its quarterly earnings, showing the company fell just short on the analyst EPS estimate of $1.34 with an actual EPS of $1.32. Alnylm did surpass analyst calls on its revenue, reporting $17.45 million compared to the estimate of $10.95 million.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The upside of the report boosted shares of the pharmaceutical company by nearly 14.5 percent. The stock finished at $44.96.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is down at $41.91, which is well below the average analyst target price of $67.31. Less than 2% of Vetr users are holding $ALNY in their watch lists.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.